New phase II AZUR-1 data presented at ESMO show 76% of evaluable patients with MSI-H/dMMR locally advanced rectal cancer achieved a complete response on dostarlimab alone, with no recurrences reported among responders after a median follow-up of more than two years. The headline figure is an exploratory analysis; the independently reviewed primary endpoint is still maturing.
What was announced
GSK plc (LSE:GSK) has released updated results from AZUR-1, a global, open-label, single-arm, registrational phase II trial of Jemperli (dostarlimab) monotherapy in adults with previously untreated stage II and III mismatch repair deficient or microsatellite instability-high (MSI-H/dMMR) locally advanced rectal cancer. The data were presented in a late-breaking oral session at the ESMO Congress. The release was issued on 24 October 2026 in London.
The trial enrolled 154 patients, who received 500mg of dostarlimab intravenously every three weeks for nine cycles over six months. The aim of the approach is to allow some patients to avoid chemotherapy, radiation and surgery.
The numbers
GSK (LSE:GSK) reported that 76% of patients (110 of 144; 95% CI 69%–83%) achieved a complete response, defined as an investigator-assessed clinical complete response sustained for 12 months (cCR12), a pathological complete response, or both. The company describes these efficacy figures as exploratory unless otherwise stated.
Of the 144 patients in that analysis, 68% (98 of 144; 95% CI 60%–76%) achieved an investigator-assessed sustained clinical complete response for at least 12 months without surgery. A further 12 patients had a pathological complete response confirmed by tissue analysis.
The primary endpoint is cCR12 assessed by Independent Central Review, which is still maturing. On that measure, 47% of patients (54 of 116; 95% CI 37%–56%) had reached cCR12, and a further 38 participants had a clinical complete response but had not yet reached the 12-month assessment point. GSK said AZUR-1 met its primary objective by showing that a "clinically significant proportion" of patients achieved cCR12. The release reports confidence intervals but no p-values, and it does not claim statistical significance, which is consistent with a single-arm design.
No disease recurrences were reported among responders after a median follow-up of more than two years.
On safety, serious adverse reactions occurred in 20% of patients. The most common adverse reactions were fatigue (32%), rash (22%), diarrhoea (18%) and pruritus (17%), and 3% of patients permanently discontinued treatment because of adverse reactions.
What the company and investigators said
Hesham Abdullah, Senior Vice President and Global Head of Oncology, R&D at GSK, said the data show Jemperli alone has the potential to transform treatment for eligible patients, and that avoiding chemotherapy, radiation and surgery may now be possible for some of them.
Dr Andrea Cercek of Memorial Sloan Kettering Cancer Center, the AZUR-1 principal investigator, pointed to "no disease recurrences to date after more than two years of follow-up," which she said should give physicians confidence in an organ-preservation approach. The release notes that Dr Cercek has financial interests related to GSK.
Regulatory position and what to watch next
Jemperli recently received US approval for this indication, according to the release. Regulatory reviews are ongoing in other countries through Project Orbis, a US Food and Drug Administration Oncology Center of Excellence initiative that allows concurrent review by several regulators. The release does not give timings for those decisions.
Investors will watch for the maturing Independent Central Review data on the primary endpoint, including whether the 38 patients with a clinical complete response who had not reached the 12-month point go on to meet that threshold. Longer follow-up on recurrence rates will also be relevant to how the organ-preservation approach is viewed. Further decisions from Project Orbis regulators are pending, and GSK has not disclosed sales expectations for the indication.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...